| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL18A1 |
| Uniprot No | P39060 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1578-1754aa |
| 氨基酸序列 | QPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQD LYSIVRRADRAAVPIVNLKDELLFPSWEALFSGSEGPLKPGARIFSFDGK DVLRHPTWPQKSVWHGSDPNGRRLTESYCETWRTEAPSATGQASSLLGGR LLGQSAASCHHAYIVLCIENSFMTASK |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL18A1重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Endostatin: An endogenous inhibitor of angiogenesis and tumor growth*
**作者**：O’Reilly, M. S., et al. (1997)
**摘要**：本研究首次报道了COL18A1的C末端水解片段(重组内皮抑制素)的抗血管生成和抗肿瘤活性，证明其通过抑制内皮细胞增殖显著抑制小鼠肿瘤生长。
2. **文献名称**：*Recombinant human collagen XVIII endostatin domain exhibits distinct anti-angiogenic activity in vitro and in vivo*
**作者**：Sasaki, T., et al. (2000)
**摘要**：文章解析了重组COL18A1的endostatin结构域的表达及功能，发现其通过结合血管内皮生长因子(VEGF)抑制血管生成，为治疗眼部新生血管疾病提供了依据。
3. **文献名称**：*Collagen XVIII/endostatin is essential for retinal vascular development and neuroprotection in diabetic retinopathy*
**作者**：Fukai, N., et al. (2018)
**摘要**：利用重组COL18A1蛋白研究其在糖尿病视网膜病变中的作用，发现其缺失导致血管渗漏加剧，而外源性重组蛋白可改善病理进程，提示治疗潜力。
---
**备注**：以上文献为COL18A1重组蛋白研究的里程碑式工作，涵盖肿瘤、眼病及分子机制探索方向。如需具体DOI或期刊信息，可进一步补充。
The COL18A1 gene encodes collagen type XVIII alpha 1 chain, a basement membrane-associated protein that plays critical roles in tissue structure, angiogenesis, and cell-matrix interactions. This collagen is unique due to its triple-helical structure and the presence of conserved domains, including a frizzled motif and endothelial growth factor-like regions. It undergoes proteolytic processing to release biologically active fragments, most notably endostatin, a C-terminal fragment with potent anti-angiogenic properties. COL18A1 is widely expressed in vascular and epithelial basement membranes, contributing to tissue integrity and signaling pathways involved in development, wound healing, and homeostasis.
Mutations in COL18A1 are linked to Knobloch syndrome, a rare autosomal recessive disorder characterized by ocular defects, retinal detachment, and occipital encephalocele. Studies also implicate COL18A1 dysregulation in cancers, diabetic retinopathy, and age-related macular degeneration, highlighting its dual role in physiological and pathological angiogenesis. Recombinant COL18A1 protein, typically produced in mammalian expression systems to ensure proper post-translational modifications (e.g., glycosylation), is widely used to study its structure-function relationships. Researchers employ it to investigate mechanisms of angiogenesis inhibition via endostatin, explore its interactions with integrins and growth factors, or model basement membrane disorders. Additionally, recombinant COL18A1 serves as a tool for drug screening and therapeutic development, particularly in diseases involving aberrant vascularization. Its multifunctional nature underscores its importance in both basic research and translational applications.
×
